This report was supported by the Grant from Japanese Ministry of Health, Welfare and Labor.
Recent advances of radiofrequency ablation for early hepatocellular carcinoma
Article first published online: 4 JAN 2011
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Special Issue: Silver Jubilee Supplement: Celebrating 25 years of JGH
Volume 26, Issue Supplement s1, pages 115–122, January 2011
How to Cite
Izumi, N. (2011), Recent advances of radiofrequency ablation for early hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 26: 115–122. doi: 10.1111/j.1440-1746.2010.06543.x
Conflict of interest The author does not have any potentical conflicts of interest to disclose.
- Issue published online: 4 JAN 2011
- Article first published online: 4 JAN 2011
- Hepatocellular carcinoma;
- radiofrequency ablation;
- transarterial chemoembolization;
- des-gamma-crboxy prothrombin time (DCP);
- alpha-fetoprotein (AFP)
Hepatocellular carcinoma (HCC) is the third leading cause of death in the malignant neoplastic diseases in the world. Surgical operation is sometimes not indicated because of complicated liver cirrhosis and extrahepatic disorders. Radiofrequency ablation has been developed as a less invasive treatment for HCC since 1999, and long-term outcome has been shown. There are several complications which should be paid attention, and to improve the prognosis, combination treatment with transarterial chemoembolization should be discussed. Overall survival after between RFA and surgical resection should be compared prospectively. Establishment of staging system for treatment allocation of HCC and prevention of HCC recurrence is important issue to be examined.